8-K: Altria Faces E-Vapor Setbacks, Reports Sharp Earnings Drop

Sentiment:

Annual Financial Results 29 January 2026 7:20 AM

Altria Group, Inc. reported a significant decline in net earnings and EPS for 2025, driven by substantial impairments in its e-vapor segment and ongoing regulatory challenges.

Delay expectedThe ITC exclusion order and cease-and-desist orders for NJOY ACE, effective March 31, 2025, prohibit its importation and sale in the United States, effectively delaying its commercialization.Management evaluated the current enforcement environment against illicit flavored disposable e-vapor products and deemed any effective enforcement would likely occur gradually over a longer period of time, implying a delay in market normalization for lawful e-vapor products.

Capital raiseIn the third quarter of 2025, Altria issued U.S. dollar denominated senior unsecured notes in the aggregate principal amount of $1.0 billion.In the first quarter of 2025, Altria issued U.S. dollar denominated senior unsecured notes in the aggregate principal amount of $1.0 billion.

Worse than expectedNet earnings for 2025 decreased by 38.33% compared to 2024, and EPS decreased by 37.00%.The e-vapor reporting unit incurred total non-cash goodwill impairments of $1,158 million in 2025.E-vapor definite-lived intangible assets incurred a non-cash, pre-tax impairment of $970 million in 2025.The ITC issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, effective March 31, 2025, significantly hindering a key growth product.Total stockholders' equity (deficit) worsened to $(3,452) million in 2025 from $(2,188) million in 2024.

Summary

Net revenues for 2025 decreased to $23,279 million from $24,018 million in 2024 and $24,483 million in 2023.
Net earnings for 2025 plummeted to $6,947 million, a significant drop from $11,264 million in 2024 and $8,130 million in 2023.
Basic and diluted earnings per share (EPS) for 2025 were $4.12, down from $6.54 in 2024 and $4.57 in 2023.
The e-vapor reporting unit incurred non-cash goodwill impairments totaling $1,158 million in 2025, primarily due to the U.S. International Trade Commission's (ITC) exclusion order for NJOY ACE and protracted ineffective enforcement against illicit flavored disposable e-vapor products.
E-vapor definite-lived intangible assets also faced a non-cash, pre-tax impairment of $970 million in 2025.
A non-cash, pre-tax impairment of $354 million was recorded for the Skoal trademark in 2024 due to increased competition from innovative tobacco products.
The company's total stockholders' equity (deficit) worsened to $(3,452) million in 2025 from $(2,188) million in 2024.
Altria's Board of Directors approved a 3.9% increase in the quarterly dividend rate to $1.06 per share, resulting in an annualized rate of $4.24 per share.
The company issued $2.0 billion in new U.S. dollar denominated senior unsecured notes in 2025 and repaid $1.607 billion in long-term debt.
An Optimize & Accelerate Initiative, designed to modernize ways of working, had estimated total pre-tax charges updated to approximately $175 million in Q4 2025, with the majority of remaining charges expected by the end of 2027.
The company settled the majority of the Multidistrict Litigation lawsuits and consolidated California state court proceedings related to JUUL e-vapor products for $235 million in 2023, paid in Q2 2024, and an additional $20 million for Native American tribes settlement in 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to significant impairments in the e-vapor segment, declining revenues and net earnings, and ongoing regulatory and legal challenges that cloud future growth prospects, despite some positive cash flow and dividend increases.

Positives

Net cash provided by operating activities increased to $9,290 million in 2025 from $8,753 million in 2024.
The Board of Directors approved a 3.9% increase in the quarterly dividend rate to $1.06 per share, an annualized rate of $4.24 per share.
The company extended its $3.0 billion senior unsecured 5-year revolving credit agreement from October 24, 2028, to October 24, 2029.
Altria completed a $1.0 billion share repurchase program in 2025, with $1.0 billion remaining under the current program expiring December 31, 2026.
PM USA obtained releases and dismissal of claims in Canadian tobacco product-related litigation, with no responsibility for payments due to indemnification obligations.

Negatives

Net revenues declined by 3.08% in 2025 to $23,279 million from $24,018 million in 2024.
Net earnings decreased by 38.33% in 2025 to $6,947 million from $11,264 million in 2024.
Basic and diluted EPS decreased by 37.00% in 2025 to $4.12 from $6.54 in 2024.
Operating income decreased by 11.93% in 2025 to $9,899 million from $11,241 million in 2024.
The e-vapor reporting unit incurred total non-cash goodwill impairments of $1,158 million in 2025.
E-vapor definite-lived intangible assets incurred a non-cash, pre-tax impairment of $970 million in 2025.
The ITC issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, effective March 31, 2025, due to patent infringement.
Total stockholders' equity (deficit) worsened to $(3,452) million in 2025 from $(2,188) million in 2024.
Long-term debt increased to $24,140 million in 2025 from $23,399 million in 2024.
A U.S. District Court ruled in favor of the IRS, denying Altria's refund claim for the 2017 tax year related to downward attribution rules, leading to a $348 million reserve for 2018-2025 tax years.

Risks

Unfavorable outcomes or settlements in pending or future litigation, including tobacco-related and other cases, could materially affect consolidated results, cash flows, or financial position.
Challenges to state bond cap statutes in tobacco litigation could prevent obtaining relief from bonding requirements, potentially impacting liquidity.
Future non-cash impairments of the e-vapor reporting unit goodwill could occur if assumptions or judgments regarding the e-vapor category and NJOY's business fail to materialize, or if the discount rate increases.
General macroeconomic conditions, governmental actions (including FDA regulatory actions and inaction), changes in e-vapor category growth rates, success of new product expansions, and competitive activity could impact impairment conclusions.
Unfavorable outcomes with respect to litigation proceedings, including actions alleging patent infringement, could lead to additional impairments.
The outcome of appeals related to NPM Adjustment disputes (e.g., New Mexico) may affect the final amount of adjustments received.
Disputes under State Settlement Agreements, such as those concerning tax rates in profit adjustment payments (e.g., Texas, Minnesota), could result in additional payments.
Ongoing e-vapor patent litigation (e.g., JUUL vs. NJOY Daily, NJOY vs. JUUL) could lead to further exclusion orders, injunctions, or damages.
Antitrust litigation against Altria and JUUL could result in treble damages, attorneys' fees, or rescission of transactions.
Environmental laws and regulations could impose additional remediation costs or damages.

Future Outlook

Management anticipates recording the majority of the remaining $51 million in charges for the Optimize & Accelerate Initiative by the end of 2027. The company expects to receive various credits and payments from NPM Adjustment settlements in 2026. The ITC orders prohibiting NJOY ACE sales will remain in effect during the appeal process. Several e-vapor patent litigation cases have scheduled hearings and expected determinations in 2026 and 2027. An evidentiary hearing regarding royalties in the R.J. Reynolds patent litigation is estimated for February or March 2026, and the antitrust litigation trial is set for May 2026. Employer contributions to pension and postretirement plans are estimated to be up to $60 million and $100 million, respectively, in 2026. The $1.0 billion remaining under the January 2025 share repurchase program is expected to be utilized by December 31, 2026.

Management Comments

Salvatore Mancuso, Executive Vice President and Chief Financial Officer, duly caused this report to be signed on behalf of Altria Group, Inc.

Industry Context

StockSavvy.ai notes that Altria's significant impairments in its e-vapor segment highlight the intense regulatory scrutiny and competitive pressures within the evolving tobacco industry. The ITC's exclusion order for NJOY ACE underscores the high-stakes nature of patent litigation and regulatory authorizations for novel tobacco products. The company's acknowledgment of 'protracted ineffective enforcement against illicit flavored disposable e-vapor products' points to a broader industry challenge where unregulated products undermine the market for compliant alternatives. The impairment of the Skoal trademark also reflects a continuing shift in consumer preferences away from traditional moist smokeless tobacco towards newer oral nicotine products, a trend impacting established players across the sector.

Comparison to Industry Standards

The e-vapor segment's challenges, particularly the ITC exclusion order for NJOY ACE, are comparable to regulatory hurdles faced by other companies attempting to introduce novel tobacco products, such as Juul Labs, which has also faced extensive litigation and regulatory scrutiny for its e-vapor devices.
The decline in traditional tobacco products, evidenced by the Skoal trademark impairment, aligns with broader industry trends where companies like British American Tobacco (BAT) and Imperial Brands are also investing heavily in 'new categories' (e.g., Vuse, glo) to offset declines in combustible cigarette sales.
Altria's dividend increase, despite declining earnings, reflects a common strategy among mature tobacco companies to return capital to shareholders, similar to practices seen at BAT and Philip Morris International (PMI), which often maintain high dividend yields even amidst market shifts.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Plan Adoption	Adopted the 2025 Performance Incentive Plan, allowing the grant of various stock-based and cash-based incentive awards to employees, with up to 25 million shares of common stock issuable through the 2035 Annual Meeting of Shareholders.	2025-01-01	Enhances employee incentives and aligns with long-term performance goals, replacing the 2020 plan.
Plan Adoption	Adopted the 2025 Stock Compensation Plan for Non-Employee Directors, allowing the grant of up to one million shares of common stock to non-employee directors through the 2035 Annual Meeting of Shareholders.	2025-01-01	Provides equity-based compensation for non-employee directors, replacing the 2015 plan.
Credit Agreement Extension	Extended the $3.0 billion senior unsecured 5-year revolving credit agreement from October 24, 2028, to October 24, 2029.	2025-07-01	Maintains liquidity and financial flexibility for general corporate purposes for an extended period.

Legal Proceedings

Approximately 48 state court Engle progeny cases are pending against PM USA or Altria as of January 26, 2026, with two cases set for trial through March 31, 2026.
PM USA and Altria have obtained releases and dismissal of claims in seven smoking and health class actions, ten health care cost recovery actions, and four e-vapor class actions in Canada due to a settlement plan implemented in August 2025 by other Canadian tobacco manufacturers.
PM USA continues to make annual payments under the State Settlement Agreements (MSA), totaling approximately $3.0 billion in 2025.
Ongoing NPM Adjustment disputes with states that have not settled, including for 2004 and 2005-2007, with potential impacts on future MSA payments.
PM USA is appealing a U.S. District Court ruling in favor of the State of Texas, finding PM USA owes $31 million plus interest concerning tax rates in profit adjustment payments.
PM USA intends to appeal a Minnesota state court order finding PM USA owes the State of Minnesota $10 million plus interest concerning tax rates in profit adjustment payments.
JUUL and VMR Products LLC filed a lawsuit and a related ITC action against Altria and affiliates alleging patent infringement based on NJOY ACE, resulting in an ITC exclusion order and cease-and-desist orders effective March 31, 2025, which Altria is appealing.
NJOY filed a lawsuit and a related ITC action against JUUL alleging patent infringement based on JUUL products; the ITC investigation found no infringement, and NJOY dismissed its appeal but moved to lift the stay on the District Court lawsuit.
JUUL filed a lawsuit and a related ITC action against Altria and affiliates alleging patent infringement based on NJOY Daily, with an ITC hearing scheduled for April 2026 and final determination expected in January 2027.
Altria and affiliates sued the ITC and ALJ in U.S. District Court seeking to enjoin adjudication of JUUL's action against NJOY Daily, asserting claims of unconstitutional appointment and right to a jury trial.
NJOY Holdings and NJOY filed a petition with PTAB challenging the validity of the patent underlying JUUL's August 2025 actions against NJOY Daily.
NJOY filed an additional lawsuit and related ITC action against JUUL alleging patent infringement based on JUUL products, with an ITC hearing scheduled for September 2026 and final determination expected in April 2027.
ALCS was awarded $95 million in damages and a 5.25% royalty on future sales in a patent infringement lawsuit against R.J. Reynolds, affirmed on appeal, with the U.S. Supreme Court denying R.J. Reynolds' petition; further district court proceedings are scheduled for February or March 2026 regarding royalties after R.J. Reynolds obtained a sublicense.
17 putative class action antitrust lawsuits are pending against Altria and JUUL, alleging violations of antitrust and consumer protection laws, with a trial set to commence in May 2026.
Altria and former subsidiaries are involved in several cost recovery/contribution cases related to environmental regulation under Superfund or other laws.

Related Party Transactions

Under a distribution agreement with Philip Morris International Inc. (PMI), PMI indemnifies Altria and PM USA for liabilities related to tobacco products manufactured by PMI, and PM USA indemnifies PMI for liabilities related to tobacco products manufactured by PM USA (excluding contract manufactured for PMI).
Altria guarantees the financial obligations of ALCS under a voluntary supplier financing program facilitated through a third-party intermediary.

Stakeholder Impact

Shareholders are impacted by the significant decline in net earnings and EPS, the worsening stockholders' equity deficit, but also benefit from an increased dividend and ongoing share repurchase program.
Employees are affected by the Optimize & Accelerate Initiative, which includes employee separation costs as part of modernizing ways of working.
Customers of NJOY ACE are impacted by the ITC's exclusion order, which prohibits the importation and sale of the product in the U.S.
Creditors are impacted by the increase in long-term debt, but Altria remains in compliance with its credit agreement covenants, and PM USA guarantees Altria's debt obligations.
Regulatory authorities are actively involved in the company's operations, particularly the FDA and ITC, impacting product commercialization and market access.

Next Steps

Record the majority of the remaining $51 million in charges for the Optimize & Accelerate Initiative by the end of 2027.
Receive $28 million from the Massachusetts NPM Adjustment settlement in April 2026.
Receive a $53 million credit against the 2026 MSA payment to the State of Washington.
Receive an insignificant credit against the April 2026 MSA payment to U.S. territories.
Appeal the U.S. District Court's ruling in favor of the IRS regarding downward attribution rules for the 2017 tax year.
Appeal the Texas State Settlement Agreement ruling where PM USA owes $31 million to the State of Texas.
Appeal the Minnesota State Settlement Agreement ruling where PM USA owes $10 million to the State of Minnesota.
Continue appeal of the ITC's exclusion order and cease-and-desist orders prohibiting NJOY ACE importation and sale.
Continue appeal of the PTAB's decision regarding NJOY ACE patent validity.
Proceed with NJOY's lawsuit against JUUL in the U.S. District Court for the District of Delaware after lifting the stay.
Attend ITC hearing in April 2026 for JUUL's patent infringement action against NJOY Daily, with an initial determination expected in September 2026 and final determination in January 2027.
Pursue summary judgment and preliminary injunction in Altria's lawsuit against the ITC and ALJ regarding JUUL's action against NJOY Daily.
Attend ITC hearing in September 2026 for NJOY's patent infringement action against JUUL products, with an initial determination expected in December 2026 and final determination in April 2027.
Participate in an evidentiary hearing in February or March 2026 regarding royalties in the R.J. Reynolds patent litigation after R.J. Reynolds obtained a sublicense.
Commence trial for the consolidated antitrust lawsuits in May 2026.
Make employer contributions of up to approximately $60 million to pension plans and $100 million to postretirement plans in 2026.
Utilize the remaining $1.0 billion under the January 2025 share repurchase program by December 31, 2026.

Key Dates

Date	Description
1997-01-01	Issuance date of USD debenture, 7.75%, due 2027.
1998-11-01	PM USA and other tobacco product manufacturers entered into the Master Settlement Agreement (MSA).
1999-01-01	Start of period for trial results in tobacco-related cases where PM USA was a defendant.
2004-10-01	Start of period for judgments and settlements paid by PM USA in Engle progeny litigation.
2006-07-01	Florida Supreme Court mandated decertification of the Engle class, allowing individual actions.
2007-01-01	Acquisition of Middleton, resulting in cigar trademarks of $2.6 billion.
2008-01-01	Deadline for filing Engle progeny cases expired.
2008-01-01	Spin-off of former subsidiary PMI and entry into Distribution Agreement.
2008-11-01	Issuance date of USD notes, 9.950%, due 2038.
2009-01-01	Acquisition of UST, resulting in MST trademarks of $8.5 billion.
2009-02-01	Issuance date of USD notes, 10.200%, due 2039.
2012-08-01	Issuance date of USD notes, 4.250%, due 2042.
2013-05-01	Issuance date of USD notes, 4.500%, due 2043.
2013-10-01	Issuance date of USD notes, 5.375%, due 2044.
2015-01-01	PM USA entered into a separate NPM Adjustment settlement with the State of New York.
2016-09-01	Issuance date of USD notes, 2.625%, due 2026 and USD notes, 3.875%, due 2046.
2017-01-01	U.S. federal income tax statute of limitations remains open from this year forward.
2019-02-01	Issuance date of USD notes, 4.400%, due 2026; Euro notes, 2.200%, due 2027; USD notes, 4.800%, due 2029; USD notes, 5.800%, due 2039; USD notes, 5.950%, due 2049; and USD notes, 6.200%, due 2059.
2019-03-01	Canadian class actions were stayed due to three Canadian tobacco manufacturers seeking protection under Canada's Companies Creditors Arrangement Act.
2020-05-01	Issuance date of USD notes, 3.400%, due 2030 and USD notes, 4.450%, due 2050.
2020-01-01	PM USA entered into a separate NPM Adjustment settlement with the State of Montana.
2021-02-01	Issuance date of USD notes, 2.450%, due 2032; USD notes, 3.400%, due 2041; USD notes, 3.700%, due 2051; and USD notes, 4.000%, due 2061.
2022-09-01	Jury awarded ALCS $95 million in damages for past infringement against R.J. Reynolds.
2022-10-01	Agreement to settle federal and state shareholder derivative cases related to former investment in JUUL.
2022-10-01	Purchase agreement entered into with PMI for the assignment of IQOS System commercialization rights.
2022-12-31	Carrying value of investment in JUUL was $250 million.
2023-01-01	Board authorized a $1.0 billion share repurchase program.
2023-01-01	Court ordered R.J. Reynolds to pay ALCS a 5.25% royalty on future sales of its infringing product.
2023-03-01	Entered into a stock purchase agreement with JUUL to transfer all JUUL equity securities.
2023-05-01	Federal and state shareholder derivative settlement became effective.
2023-05-01	Fuma International LLC filed a lawsuit against Altria and affiliates asserting patent infringement.
2023-05-01	Reached agreement on terms to resolve the majority of the Multidistrict Litigation lawsuits and consolidated California state court proceeding for $235 million.
2023-06-01	Acquired NJOY Holdings (NJOY Transaction).
2023-06-01	JUUL and VMR Products LLC filed a lawsuit against Altria and affiliates asserting patent infringement based on NJOY ACE.
2023-06-01	JUUL and VMR Products LLC filed a related action against Altria and affiliates with the ITC.
2023-07-01	Repaid the $2.0 billion term loan facility in full.
2023-08-01	Entered into an agreement with Fuma resulting in NJOY's acquisition of patents, and Fuma dismissed patent infringement claims for $10 million.
2023-08-01	NJOY filed a complaint against JUUL in the U.S. District Court for the District of Delaware asserting patent infringement.
2023-08-01	NJOY filed a related action against JUUL with the ITC alleging patent infringement.
2023-10-01	Annual impairment test of goodwill and indefinite-lived intangible assets performed.
2023-10-01	Court issued an order as to damages, finding PM USA owes the State of Minnesota $10 million plus preand post-judgment interest.
2023-10-01	U.S. Supreme Court denied R.J. Reynolds' petition to review the federal appellate court's affirmance of the federal district court's judgment.
2023-10-01	PM USA and R.J. Reynolds filed a motion in the U.S. District Court for the Eastern District of Texas seeking to enforce the Texas State Settlement Agreement.
2023-11-01	Issuance date of USD notes, 6.200%, due 2028 and USD notes, 6.875%, due 2033.
2023-11-01	JUUL filed petitions with the PTAB challenging the validity of NJOY's patent infringement claims.
2023-11-01	Altria and affiliates filed petitions with the U.S. Patent Office Patent Trial and Appeal Board (PTAB) challenging the validity of patents underlying JUUL and VMR's patent infringement claims.
2023-12-01	Completed the January 2023 share repurchase program.
2023-12-01	ALJ issued an initial determination concluding that JUUL products do not infringe NJOY's asserted patents.
2024-01-01	Board authorized a $1.0 billion share repurchase program, expanded to $3.4 billion in March 2024.
2024-01-01	R&D expense alignment with CODM evaluation for segment reporting began.
2024-01-01	First quarter of 2024, Altria converted 60 million of its Restricted Shares into ordinary shares of ABI and completed the sale of a portion of its investment in ABI (ABI Transaction).
2024-03-01	Court granted final approval of the class action settlement for JUUL e-vapor product litigation.
2024-04-01	Assigned the exclusive U.S. commercialization rights to the IQOS Tobacco Heating System (IQOS System) to Philip Morris International Inc. (PMI).
2024-05-01	PTAB denied Altria's requests to institute review as to four patents and granted for one patent.
2024-06-01	PTAB agreed to review JUUL's challenge to both of the NJOY patents asserted against JUUL.
2024-06-30	Interim impairment assessment performed for Skoal trademark.
2024-07-01	State of Minnesota filed a motion in Minnesota state court seeking to enforce the Minnesota State Settlement Agreement.
2024-07-01	Separately agreed to settle cases brought by Native American tribes related to JUUL e-vapor products.
2024-08-01	Canadian tobacco manufacturers' plan was implemented, resulting in releases for Altria and PM USA.
2024-09-01	PM USA and the State of Mississippi settled their dispute over profit adjustment payments.
2024-10-01	Announced a multi-phase Optimize & Accelerate initiative.
2024-10-01	Paid settlement amount for Native American tribes in JUUL e-vapor product litigation.
2024-10-01	PM USA entered into a separate NPM Adjustment settlement with the Commonwealth of Massachusetts.
2024-10-24	Original expiration date of the $3.0 billion senior unsecured 5-year revolving credit agreement.
2024-12-01	Federal appellate court affirmed the judgment in ALCS vs. R.J. Reynolds patent litigation.
2024-12-01	District court denied R.J. Reynolds' motion to vacate judgment as to damages award and royalties due through December 2023.
2024-12-01	Completed the January 2024 share repurchase program.
2025-01-01	Board authorized a new $1.0 billion share repurchase program, expanded to $2.0 billion in October 2025.
2025-01-01	ITC issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States.
2025-02-01	Issuance date of USD notes, 4.875%, due 2028 and USD notes, 5.625%, due 2035.
2025-03-01	U.S. District Court issued a final order in the Texas State Settlement Agreement matter, finding PM USA owes $31 million to the State of Texas.
2025-03-31	ITC orders prohibiting the importation and sale of NJOY ACE became effective.
2025-05-01	PTAB issued its decision concluding that the patent it reviewed was valid in JUUL/VMR vs Altria/NJOY patent litigation.
2025-05-01	Altria appealed the ITC's final determination in NJOY vs JUUL patent litigation.
2025-05-31	No new awards permitted under the 2020 Performance Incentive Plan.
2025-06-01	PTAB issued its decision concluding that the patents it reviewed were valid in JUUL's challenge to NJOY patents.
2025-07-01	Entered into an agreement to extend the expiration of the $3.0 billion senior unsecured 5-year revolving credit agreement.
2025-07-01	Voluntarily dismissed the appeal of the ITC's final determination in NJOY vs JUUL patent litigation.
2025-07-01	The One Big Beautiful Bill Act (OBBB) was signed into law.
2025-08-01	Issuance date of USD notes, 4.500%, due 2030 and USD notes, 5.250%, due 2035.
2025-08-01	JUUL filed an additional lawsuit against Altria and affiliates asserting patent infringement based on NJOY Daily.
2025-08-01	JUUL filed a related action against Altria and affiliates with the ITC.
2025-09-01	U.S. District Court for the Eastern District of Virginia ruled in favor of the IRS denying Altria's refund claim for the 2017 tax year.
2025-09-01	NJOY filed an additional complaint against JUUL in the U.S. District Court for the District of Delaware asserting patent infringement.
2025-09-01	NJOY, ALCS, and AGDC filed a related action against JUUL with the ITC alleging patent infringement.
2025-10-01	Annual impairment test of goodwill and indefinite-lived intangible assets performed.
2025-10-01	NJOY moved to lift the stay on NJOY's lawsuit against JUUL in the U.S. District Court for the District of Delaware.
2025-11-01	Altria and affiliates sued the ITC and the ALJ in the U.S. District Court for the Eastern District of Virginia.
2025-11-01	NJOY Holdings and NJOY filed a petition with PTAB challenging the validity of the patent underlying JUUL's August 2025 actions.
2025-12-31	End of fiscal year for which the current report on Form 8-K is filed.
2026-01-01	The OBBB reinstates the downward attribution rule, limiting the impact of the IRS ruling to the 2017-2025 tax years.
2026-01-26	Date as of which two Engle progeny cases, one individual smoking and health case, and no e-vapor cases are set for trial through March 31, 2026.
2026-01-29	Date of report for Form 8-K and date of independent registered public accounting firm's report.
2026-02-06	Beginning date for semi-annual interest payments on $0.5 billion notes due 2030 and $0.5 billion notes due 2035.
2026-04-01	PM USA expects to receive $28 million from the Massachusetts NPM Adjustment settlement.
2026-04-01	PM USA will receive a $53 million credit against its MSA payment due to the State of Washington.
2026-04-01	PM USA will receive an insignificant credit against its April 2026 MSA payment to U.S. territories.
2026-04-01	Hearing before the ALJ scheduled for JUUL's ITC action against NJOY Daily.
2026-09-01	Expected initial determination from the ALJ in JUUL's ITC action against NJOY Daily.
2026-09-01	Hearing before the ALJ scheduled for NJOY's ITC action against JUUL products.
2026-12-31	Expiration date of the $1.0 billion remaining under the January 2025 share repurchase program.
2026-12-01	Expected initial determination from the ALJ in NJOY's ITC action against JUUL products.
2027-01-01	Expected final determination from the ITC in JUUL's ITC action against NJOY Daily.
2027-12-31	Expected completion of the majority of remaining charges for the Optimize & Accelerate Initiative.
2027-04-01	Expected final determination from the ITC in NJOY's ITC action against JUUL products.
2028-12-31	JUUL-related gross capital loss carryforwards of $1.4 billion available to offset capital gains through this year.
2029-10-24	Extended expiration date of the $3.0 billion senior unsecured 5-year revolving credit agreement.
2030-12-31	PM USA settled NPM Adjustment disputes with the State of Montana through this year.
2031-12-31	Year that the health care cost trend rate reaches the ultimate trend rate of 5.0%.
2035-01-01	Expiration of relevant patents in ALCS vs. R.J. Reynolds patent litigation, impacting royalty payments.
2035-05-31	Date of Altria's Annual Meeting of Shareholders through which shares may be issued under the 2025 Performance Incentive Plan and 2025 Stock Compensation Plan for Non-Employee Directors.
2041-12-31	PM USA expects to receive annual credits against MSA payments through this year from the multi-state settlement.

Recommendation

sell

The significant decline in net earnings and EPS for 2025, coupled with substantial impairments in the e-vapor segment and ongoing regulatory and legal challenges, indicates a deteriorating fundamental outlook. While the company maintains a strong dividend and positive operating cash flow, the core business is under pressure, and key growth initiatives like NJOY are facing severe headwinds. The worsening stockholders' equity deficit and increasing long-term debt further contribute to a cautious stance. Seasoned investors would likely view these developments as a signal to reduce exposure given the uncertainty and declining profitability in critical growth areas.

Keywords

Altria, MO, SEC Filing, 8-K, Financial Results, Earnings, EPS, E-vapor, NJOY, Goodwill Impairment, Intangible Asset Impairment, Tobacco Industry, Dividend, Share Repurchase, Litigation, Patent Infringement, Regulatory Risk, FDA, ITC, Skoal, ABI, Cronos, Debt, Cash Flow

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.